Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Rhea-AI Summary
Cognition Therapeutics (NASDAQ: CGTX) received a USPTO Notice of Allowance for patent application 19/563,468 covering a polymorphic crystalline form of its lead candidate zervimesine (CT1812).
According to Cognition Therapeutics, the patent is expected to protect this formulation through 2045, or potentially 2050 with a standard 5‑year extension, and covers composition of matter, production process, and therapeutic methods for age‑related neurodegenerative disorders including Alzheimer’s disease, geographic atrophy, and dementia with Lewy bodies (DLB). The company reports this polymorphic form has greater thermodynamic and chemical stability and expects to use it in planned registrational trials of zervimesine for DLB psychosis following recent FDA discussions.
Positive
- USPTO Notice of Allowance for zervimesine patent application 19/563,468
- Patent protection for zervimesine formulation expected through 2045, possibly 2050 with extension
- Patent covers composition of matter, production process, and therapeutic methods
- New polymorphic form described as more thermodynamically and chemically stable
- Company plans to employ new form in registrational trials for DLB psychosis
Negative
- Patent is at Notice of Allowance stage and not yet formally issued
- Company is awaiting FDA meeting minutes to confirm registrational program next steps
News Market Reaction – CGTX
In the Jun 16 session, CGTX gained 4.13%, reflecting a moderate positive market reaction. Argus tracked a peak move of +15.2% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Investor conferences | Positive | +5.9% | Announced participation in June 2026 investor conferences with DLB psychosis updates. |
| May 21 | FDA meeting update | Positive | -3.1% | Reported productive FDA meeting on Phase 2 data and registrational design for DLB psychosis. |
| May 14 | EAP funding donation | Positive | +0.0% | Received second philanthropic donation extending expanded access program for DLB patients. |
| May 07 | Q1 2026 earnings | Positive | +4.3% | Reported Q1 2026 results, outlined cash runway and zervimesine clinical plans. |
| Apr 07 | Conference presentation | Neutral | -2.4% | Announced upcoming Needham virtual presentation on Alzheimer’s and DLB programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CGTX news often shows mixed alignment: FDA and program updates sometimes trade against the seemingly positive narrative.
Over the last few months, Cognition Therapeutics has focused disclosures on zervimesine (CT1812) and its DLB psychosis and Alzheimer’s programs. FDA interactions and registrational‑design dialogue on May 20, 2026, philanthropy‑supported expanded access, and Q1 2026 results highlighting cash runway into Q2 2027 frame a company preparing for late‑stage studies. Conference participation and investor decks emphasized DLB psychosis as the lead indication. Today’s patent allowance extending protection for the polymorphic crystalline form of zervimesine fits into this pattern of de‑risking and solidifying the lead asset.
Key Terms
notice of allowance regulatory
united states patent and trademark office regulatory
composition of matter regulatory
polymorphic crystalline form medical
geographic atrophy medical
dementia with lewy bodies medical
registrational trials medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.
The allowed patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate. Once issued, the patent will provide protection for this key formulation through 2045 and, if granted a standard 5-year extension, could offer protection through 2050.
Titled “Crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salt,” this patent application covers:
- Composition of Matter: a polymorphic crystalline form of zervimesine.
- Production Process: A specialized, proprietary process for producing zervimesine.
- Therapeutic Methods: Methods of treating highly underserved, age-related degenerative disorders including Alzheimer’s disease, geographic atrophy, and dementia with Lewy bodies (DLB).
While containing the same molecular components as the parent compound, the new configuration of this polymorphic form of zervimesine creates a more favorable pharmaceutical profile with greater thermodynamic and chemical stability.
“The advancement of zervimesine reflects our commitment to developing transformative therapies for people living with neurodegenerative diseases like DLB, a devastating disease with no approved treatments,” said Anthony Caggiano, M.D., Ph.D., chief medical officer of Cognition Therapeutics. “We held productive discussions with the FDA in May regarding key aspects of our registrational program and are awaiting meeting minutes to confirm alignment on next steps. We expect to employ this new form of zervimesine in those registrational trials of zervimesine for DLB psychosis.”
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly
About Zervimesine (CT1812)
Zervimesine (CT1812) is currently being studied in the Phase 2 START Study (NCT05531656) in patients with MCI and early Alzheimer’s disease. Phase 2 clinical studies have concluded in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. Based in part on the strong efficacy signals observed in the Phase 2 SHIMMER study in DLB (NCT05225415), the company plans to advance zervimesine into a late-stage clinical trial for people with DLB psychosis. Zervimesine has been generally well tolerated in clinical studies to date.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash runway, our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
